Abstract
The need of using chemically modified siRNA agents for gene silencing continuously increasing as appropriate chemical modification improves their specificity, nuclease stability, potency, and in vivo cellular delivery. The future success of RNAi technology also depends on identifying drug carriers that are non-toxic and tissue-specific in directing the RNAi agents to the desired locations in a cost effective fashion. This review will cover recently reported chemically modified siRNA agents for improving specificity and potency of mRNA knockdown, their nuclease stability, cellular uptake and improved biodistribution. In addition to the chemical modifications and their biological impact, this review also focuses on the in vivo RNAi delivery techniques.
Keywords: Chemical modification, siRNA, RNA interference, RNAi agents, Gene-silencing, miRNA, In vivo RNAi
Current Bioactive Compounds
Title: Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques
Volume: 4 Issue: 1
Author(s): Anilkumar R. Kore and Lance P. Ford
Affiliation:
Keywords: Chemical modification, siRNA, RNA interference, RNAi agents, Gene-silencing, miRNA, In vivo RNAi
Abstract: The need of using chemically modified siRNA agents for gene silencing continuously increasing as appropriate chemical modification improves their specificity, nuclease stability, potency, and in vivo cellular delivery. The future success of RNAi technology also depends on identifying drug carriers that are non-toxic and tissue-specific in directing the RNAi agents to the desired locations in a cost effective fashion. This review will cover recently reported chemically modified siRNA agents for improving specificity and potency of mRNA knockdown, their nuclease stability, cellular uptake and improved biodistribution. In addition to the chemical modifications and their biological impact, this review also focuses on the in vivo RNAi delivery techniques.
Export Options
About this article
Cite this article as:
Kore R. Anilkumar and Ford P. Lance, Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques, Current Bioactive Compounds 2008; 4 (1) . https://dx.doi.org/10.2174/157340708784533375
DOI https://dx.doi.org/10.2174/157340708784533375 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Therapeutic Potential of Natural Compounds in Lung Cancer
Current Medicinal Chemistry Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Mucosal T Cell Proliferation and Apoptosis in Inflammatory Bowel Disease
Current Drug Targets The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Cytokinin Nucleosides - Natural Compounds with a Unique Spectrum of Biological Activities
Current Topics in Medicinal Chemistry Acetylome Regulation by Sirtuins in the Brain: From Normal Physiology to Aging and Pathology
Current Pharmaceutical Design Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein
Current Medicinal Chemistry Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry HIV-1 Vpr: Regulator of Viral Survival
Current HIV Research The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies
Current Pharmaceutical Design COX-2 Inhibition in Esophagitis, Barretts Esophagus and Esophageal Cancer
Current Pharmaceutical Design The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Production of Paclitaxel and the Related Taxanes by Cell Suspension Cultures of Taxus Species
Current Drug Targets The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Current Drug Targets Invasive aspergillosis: adjunctive combination therapy
Mini-Reviews in Medicinal Chemistry